Arbutus Biopharma Corp - Common Shares, without par value (ABUS) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2015 to Q4 2025

Type / Class
Equity / Common Shares, without par value
Symbol
ABUS on Nasdaq
Shares outstanding
193,679,354
Price per share
$4.06
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
122,021,912
Total reported value
$586,904,633
% of total 13F portfolios
0%
Share change
+3,794,996
Value change
+$19,477,062
Number of holders
172
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Roivant Sciences Ltd. 20% 0% $127,808,150 38,847,462 0% Roivant Sciences Ltd. 21 Feb 2025
MORGAN STANLEY 14% +19% $122,814,997 +$20,788,104 25,910,337 +20% Morgan Stanley 31 Dec 2025
Whitefort Capital Management, LP 7% $43,783,211 13,307,967 Whitefort Capital Master Fund, LP 20 Feb 2025
Two Seas Capital LP 6.5% +22% $59,672,609 +$10,171,286 12,589,158 +21% Two Seas Capital LP 31 Dec 2025

As of 31 Dec 2025, 172 institutional investors reported holding 122,021,912 shares of Arbutus Biopharma Corp - Common Shares, without par value (ABUS). This represents 63% of the company’s total 193,679,354 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) together control 58% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
MORGAN STANLEY 14% 26,702,776 +9.2% 0.01% $128,440,353
Whitefort Capital Management, LP 6.9% 13,343,228 0% 19% $64,180,927
BlackRock, Inc. 6.7% 13,052,861 +3% 0% $62,784,261
Two Seas Capital LP 6.5% 12,589,158 +15% 3.5% $60,553,850
VANGUARD GROUP INC 4.8% 9,242,437 +2.8% 0% $44,456,122
STATE STREET CORP 3.1% 5,908,211 +44% 0% $28,418,495
ADAR1 Capital Management, LLC 2.8% 5,415,109 +87% 1.9% $26,046,674
ADAGE CAPITAL PARTNERS GP, L.L.C. 2.2% 4,339,941 -13% 0.03% $20,875,116
GEODE CAPITAL MANAGEMENT, LLC 1.9% 3,677,307 +0.3% 0% $17,691,051
Woodline Partners LP 1.1% 2,186,553 +0.97% 0.04% $10,517,320
BlackBarn Capital Partners LP 0.96% 1,850,000 -7.5% 3.2% $8,898,500
BANK OF AMERICA CORP /DE/ 0.95% 1,832,704 +26% 0% $8,815,305
Rubric Capital Management LP 0.81% 1,575,376 0% 0.09% $7,577,559
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.81% 1,562,265 +23% 0% $7,514,495
OSAIC HOLDINGS, INC. 0.7% 1,348,224 +0.73% 0.01% $6,484,957
NORTHERN TRUST CORP 0.64% 1,236,689 -4.1% 0% $5,948,475
STEMPOINT CAPITAL LP 0.51% 986,751 +380% 0.81% $4,746,272
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 0.46% 890,898 0% $4,285,220
Rangeley Capital, LLC 0.43% 840,000 0% 3.5% $4,040,400
BANK OF MONTREAL /CAN/ 0.4% 766,656 +0.18% 0% $3,687,615
GOLDMAN SACHS GROUP INC 0.38% 738,580 -66% 0% $3,552,570
Hudson Bay Capital Management LP 0.35% 675,000 -16% 0.02% $3,246,750
CITIGROUP INC 0.32% 611,149 +209% 0% $2,939,626
Quinn Opportunity Partners LLC 0.27% 514,513 0% 0.11% $2,474,808
Western Standard LLC 0.26% 507,853 0% 1.1% $2,442,773

Institutional Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 122,021,912 $586,904,633 +$19,477,062 $4.81 172
2025 Q3 118,168,575 $536,370,600 +$2,488,410 $4.54 166
2025 Q2 118,112,086 $364,964,865 +$19,645,984 $3.09 162
2025 Q1 111,778,063 $390,115,968 +$29,488,807 $3.49 167
2024 Q4 104,075,822 $340,339,884 +$3,767,856 $3.27 153
2024 Q3 101,100,254 $389,229,670 +$15,557,626 $3.85 143
2024 Q2 96,687,257 $298,333,597 +$40,873,896 $3.09 129
2024 Q1 83,370,717 $215,132,214 +$11,550,835 $2.58 118
2023 Q4 78,913,089 $197,297,266 +$10,900,831 $2.50 110
2023 Q3 70,841,695 $143,815,507 +$8,057,833 $2.03 96
2023 Q2 66,235,432 $152,407,843 +$7,387,882 $2.30 109
2023 Q1 62,470,799 $189,264,221 +$26,478,755 $3.03 120
2022 Q4 54,227,682 $126,382,359 +$17,821,528 $2.33 110
2022 Q3 46,620,587 $89,144,270 -$921,936 $1.91 121
2022 Q2 35,268 $93,574 -$3,027,847 $2.18 11
2022 Q1 43,886,769 $130,608,351 +$4,239,945 $2.98 111
2021 Q4 39,679,851 $154,349,574 +$14,066,593 $3.89 114
2021 Q3 34,872,896 $149,655,492 +$26,301,612 $4.29 96
2021 Q2 28,908,795 $87,633,862 +$7,803,555 $3.03 83
2021 Q1 25,991,001 $86,467,063 +$11,894,875 $3.33 88
2020 Q4 21,915,953 $77,813,914 -$4,704,362 $3.55 72
2020 Q3 24,142,348 $75,528,504 +$7,771,699 $3.13 60
2020 Q2 26,122,191 $47,560,467 +$748,885 $1.82 46
2020 Q1 26,281,827 $26,537,879 -$13,148,563 $1.01 44
2019 Q4 24,261,532 $67,445,419 +$11,932,336 $2.78 51
2019 Q3 19,461,984 $29,679,262 -$3,274,294 $1.52 44
2019 Q2 21,113,616 $43,982,113 -$11,240,138 $2.08 56
2019 Q1 24,075,098 $86,186,166 -$440,804 $3.58 64
2018 Q4 24,175,022 $92,584,064 -$11,019,460 $3.83 65
2018 Q3 24,015,267 $227,302,706 +$34,721,438 $9.45 86
2018 Q2 20,448,527 $149,271,310 +$19,689,424 $7.30 67
2018 Q1 18,377,666 $91,890,575 -$79,594,386 $5.00 45
2017 Q4 34,211,265 $172,779,991 +$12,813,644 $5.05 50
2017 Q3 31,250,927 $193,761,084 -$33,550,517 $6.20 51
2017 Q2 36,887,584 $132,791,952 +$3,194,137 $3.60 45
2017 Q1 36,322,621 $118,047,315 +$819,274 $3.25 50
2016 Q4 36,190,341 $88,841,049 +$4,195,879 $2.45 52
2016 Q3 33,443,140 $115,042,069 +$54,657,856 $3.44 46
2016 Q2 17,549,536 $61,069,070 -$709,869 $3.48 47
2016 Q1 17,711,768 $73,144,106 -$3,356,008 $4.13 47
2015 Q4 18,370,048 $81,745,000 -$100,433,658 $4.45 47
2015 Q3 34,854,473 $212,262,000 +$210,998,423 $6.09 52
2015 Q2 207,417 $2,460,000 +$2,460,000 $11.86 1